Drug Combination Details
| General Information of the Combination (ID: C50701) | |||||
|---|---|---|---|---|---|
| Name | Isoliquiritigenin NP Info | + | Cisplatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Colon cancer
[ICD-11: 2B90]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Decreasing Adverse Drug Reaction by This Combination | ||||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Biological
Regulation |
Increase | Serum alanine aminotransferase and aspartate aminotransferase | ||||
| Decrease | Tissue lipid peroxidation | |||||
| In-vivo Model | 2*106 CT-26 mouse colon cancer cells in (0.1 ml PBS) cultured in DMEM with 10% FBS were subcutaneously injected into the right flanks of the mice. | |||||
| Experimental
Result(s) |
Isoliquiritigenin inhibits tumor growth and protects the kidney and liver against chemotherapy-induced toxicity in a mouse xenograft model of colon carcinoma. | |||||
| Experiment 2 Reporting the Effect of This Combination | [1] | |||||
| In-vivo Model | The CT-26 mouse colon cancer cells (2*106 cells in 0.1 mL PBS) cultured in DMEM with 10% FBS were subcutaneously injected into the right flanks of the BALB/c male mice. | |||||
| Experimental
Result(s) |
Isoliquiritigenin inhibits tumor growth and protects the kidney and liver against chemotherapy-induced toxicity in a mouse xenograft model of colon carcinoma. | |||||
